EPTMF (Epitomee Medical) Return-on-Tangible-Equity: -35.55% (As of Dec. 2025)


EPTMF Epitomee Medical Ltd EPTMF
30 GF Score
Price $0.99
! 3 Warning Signs
View Full Analysis

What is Epitomee Medical Return-on-Tangible-Equity?

Epitomee Medical EPTMF 30 Return-on-Tangible-Equity is -35.55% as of Dec. 2025. GuruFocus rates EPTMF with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Epitomee Medical ranks worse than 75.86% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Epitomee Medical's annualized net income for the quarter that ended in Dec. 2025 was $-10.07 Mil. Epitomee Medical's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $28.34 Mil. Therefore, Epitomee Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -35.55%.

The historical rank and industry rank for Epitomee Medical's Return-on-Tangible-Equity or its related term are showing as below:

EPTMF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -81.12   Med: -33.19   Max: -4.26
Current: -28.51

During the past 8 years, Epitomee Medical's highest Return-on-Tangible-Equity was -4.26%. The lowest was -81.12%. And the median was -33.19%.

EPTMF's Return-on-Tangible-Equity is ranked worse than
75.86% of 758 companies
in the Medical Devices & Instruments industry
Industry Median: 4.08 vs EPTMF: -28.51

Epitomee Medical  (OTCPK:EPTMF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Epitomee Medical Return-on-Tangible-Equity Related Terms


Epitomee Medical Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Epitomee Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epitomee Medical Return-on-Tangible-Equity Chart

Epitomee Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial -40.22 -33.19 -15.31 -4.26 -28.75

Epitomee Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.84 -33.23 24.49 -22.11 -35.55

EPTMF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison

For the Medical Devices subindustry, Epitomee Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epitomee Medical Return-on-Tangible-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Epitomee Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Epitomee Medical's Return-on-Tangible-Equity falls into.


EPTMF
30GF Score
Epitomee Medical Ltd EPTMF
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Epitomee Medical Return-on-Tangible-Equity Calculation

Epitomee Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-8.612/( (33.952+25.961 )/ 2 )
=-8.612/29.9565
=-28.75 %

Epitomee Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-10.074/( (30.717+25.961)/ 2 )
=-10.074/28.339
=-35.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -35.55% mean?
Epitomee Medical (EPTMF) has a Return-on-Tangible-Equity of -35.55% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Epitomee Medical and its competitors. According to the industry distribution chart, Epitomee Medical ranks #575 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 75.9%.
Is Epitomee Medical's Return-on-Tangible-Equity too high?
Epitomee Medical's current Return-on-Tangible-Equity is -35.55%. Based on the distribution chart, Epitomee Medical ranks #575 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Epitomee Medical has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Epitomee Medical's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Epitomee Medical ranks #575 out of 758 companies for Return-on-Tangible-Equity. This places Epitomee Medical in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Epitomee Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epitomee Medical's current Return-on-Tangible-Equity is -35.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epitomee Medical stock overvalued right now?
Epitomee Medical (EPTMF) has a current Return-on-Tangible-Equity of -35.55%. The current Return-on-Tangible-Equity is -35.55%. Epitomee Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Epitomee Medical (EPTMF), the current Return-on-Tangible-Equity is -35.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Epitomee Medical Business Description

Other Exchanges EPIT:Israel
Address Tarshish 19, Caesarea, ISR, 3088900
Epitomee Medical Ltd is engaged in developing and commercializing ingestible therapeutic devices.
30GF Score

Get the complete analysis for EPTMF

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price